Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLAAT2 small interfering RNA-2
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
PLAAT2 small interfering RNA-2 is an experimental RNA interference (RNAi) agent designed to specifically silence the expression of the phospholipase A and acyltransferase 2 (PLAAT2) gene. PLAAT2, also known as HRASLS2, is an enzyme involved in lipid metabolism that has been identified as a promoter of pancreatic cancer progression and a marker for chemotherapy resistance. By binding to and inducing the degradation of PLAAT2 mRNA, this siRNA inhibits the production of the PLAAT2 protein, thereby suppressing the proliferation and invasion of pancreatic cancer cells in laboratory models. It is primarily used as a research tool to investigate the functional role of PLAAT2 and its potential as a therapeutic target in oncological settings.
- Other names
- PLAAT2 siRNAPLAAT-2 siRNAPLAAT 2 siRNAHRASLS2 small interfering RNAHRASLS-2 small interfering RNAHRASLS 2 small interfering RNAsiRNA targeting PLAAT2
02
Targets
PLAAT2 (Phospholipase A and acyltransferase 2)
Beyond the preview
Go deeper on PLAAT2 small interfering RNA-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLAAT2 small interfering RNA-2.